Abstract
Although great advancements have been witnessed in treatment results for hematopoietic tumors in recent years, development of secondary malignant tumors induced by anti-cancer drugs still remains a serious issue. We experienced a case of secondary myelodysplastic syndrome (MDS), possibly induced by cyclophosphamide (CY), which was spontaneously resolved by discontinuance of CY. A 24-year-old woman was diagnosed with follicular lymphoma in January 1998: she had developed bulky intra-abdominal lymphadenopathy, with repeated relapse and remission by several chemotherapy treatments. Remission was induced by rituximab, administered at the time of relapse in 2001, followed by administration of 50 mg/day of CY since December 2001 for the prevention of relapse. Anemia and thrombocytopenia developed around January 2003. Bone marrow aspiration revealed abnormality in two lineages and a complicated chromosomal anomaly, and the patient was diagnosed with MDS. Discontinuance of CY and administration of an anabolic steroid improved anemia and thrombocytopenia within 2 years. Bone marrow aspiration in 2006 showed improvement in morphological abnormality and disappearance of chromosomal abnormality.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
van Leeuwen FE. Risk of acute myelogenous leukaemia and myelodysplasia following cancer treatment. Baillieres Clin Haematol. 1996;9:57–85.
Leone G, Voso MT, Sica S, Morosetti R, Pagano L. Therapy related leukemias: susceptibility, prevention and treatment. Leuk Lymphoma. 2001;41:255–76.
Lenz G, Dreyling M, Schiegnitz E, Haferlach T, Hasford J, Unterhalt M, et al. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol 2004;22:4926–33.
Marisavljevic D, Rolovic Z, Ludoski-Pantic M, Djordjevic V, Novak A. Spontaneous remission in adults with primary myelodysplastic syndromes: incidence and characteristics of patients. Med Oncol. 2005;22:407–10.
Renneboog B, Hansen V, Heimann P, De Mulder A, Jannsen F, Ferster A. Spontaneous remission in a patient with therapy-related myelodysplastic syndrome (t-MDS) with monosomy 7. Br J Haematol. 1996;92:696–8.
Vadhan-Raj S, Broxmeyer HE, Spitzer G, LeMaistre A, Hultman S, Ventura G, et al. Stimulation of nonclonal hematopoiesis and suppression of the neoplastic clone after treatment with recombinant human granulocyte-macrophage colony-stimulating factor in a patient with therapy-related myelodysplastic syndrome. Blood. 1989;74:1491–8.
Seiter K, Feldman EJ, Sreekantaiah C, Pozzuoli M, Weisberger J, Liu D, et al. Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy. Leukemia. 2001;15:963–70.
Lin YW, Hamahata K, Watanabe K, Adachi S, Akiyama Y, Kubota M, et al. Repetitious appearance and disappearance of different kinds of clonal cytogenetic abnormalities after allogeneic bone marrow transplantation. Int J Hematol. 2001;74:86–9.
Pedersen-Bjergaard J, Andersen MK, Christiansen DH, Nerlov C. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood. 2002;99:1909–12.
Itoh M, Yago K, Shimada H, Tohyama K. Reversible acceleration of disease progression following cyclosporin A treatment in a patient with myelodysplastic syndrome. Int J Hematol. 2002;75:302–4.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Nakagawa, Y., Miura, K., Yamazaki, T. et al. A case of treatment-related myelodysplastic syndrome spontaneously resolved by drug discontinuance. Int J Hematol 91, 530–533 (2010). https://doi.org/10.1007/s12185-010-0511-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-010-0511-2